Cancer52 is proud to share it's Annual Review covering April 2025 to March 2025. As ever it is fantastic to review what was achieved over the year. Read Cancer52 Annual Review 2024-2025

Cancer52 is proud to launch their report ‘Improving diagnosis: Patient and clinician perspectives on increasing early diagnosis in rare and

Cancer52 is pleased to submit their Annual Review for the financial year 2023-2024 to the Charity Commission.

Released online for World Cancer Day on 4th February 2025, Cancer52 shared the 'State of the Nation report on Rare and Less Common Cancers.

Cancer52 has released its latest report on health inequalities , as part of the Big Cancer52 Conversation event. >> Read report...

Fair Market Value (FMV) Guidance is now available to bring consistency to reimbursement for cross-sector partnership work. See FMV...

Cancer52 has launched a manifesto called   ‘The Other Half. A manifesto to transform outcomes for people with rare and less common...

Cancer52 is proud to share its Annual Review for the financial year 2022-2023. As ever it is a great opportunity to look back at what has...

Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less common...

Patient charities set out a shared vision for the next VPAS scheme. Cancer52 have joined forces with the Charity Medicines Access...